Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02192502 · ClinicalTrials.gov registry record · Phase 3
Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients
A Phase 3 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 149
- Enrollment target
NCT02192502 is a Phase 3 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 149 participants.
The verdict
NCT02192502, a Phase 3 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 149 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of a standard volume replacement called HES 130/0.4 (Voluven) during surgery on recovery. HES 130/0.4 (Voluven) may offer an alternative to pure fluid replacement solutions that are associated with problems after surgery including fluid overload and respiratory difficulties. The safety of HES 130/0.4 (Voluven) will be evaluated by examining its effects on kidney function, and coagulation parameters and platelet (part of the blood that help it clot) function. Participants will be randomized (like flipping a coin) to receive one of two possible volume replacements during surgery, if fluid volume decreases enough to need replacement with one of the fluids. The two possible volume replacements are Voluven (a starch-containing fluid) or human albumin 5% (a protein-containing solution). To examine kidney function, urine will be-sampled when the participant is put under general anesthesia, before surgical incision, within one hour of arrival to the ICU and 24 hours after completion of surgery. Two tubes (2 teaspoons) of blood (from an already established line) will be taken the morning of the surgery, within one hour of arrival to the ICU, 24 hours after surgery and every morning during the participants postoperative ICU stay. Additionally, health and recovery information will be recorded from the participant's medical record. We will phone participants around 90 days and one year after surgery to ask a few questions about one's health and recovery. We will also record blood sample analysis results from follow up appointments within the first year after surgery. If this analysis is not conducted at the Cleveland Clinic, with permission, we will obtain the results from a treating physician.
Interventions
- DRUG human albumin 5%
- DRUG HES 130/0.4 (Voluven)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2015-03 |
| Est. Completion | 2020-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02192502
The ClinicalTrials.gov registry entry for NCT02192502 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which human albumin 5% is the first listed.
NCT02192502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02192502 about?
NCT02192502 is a clinical study titled "Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients". The purpose of this study is to evaluate the safety of a standard volume replacement called HES 130/0.4 (Voluven) during surgery on recovery. HES 130/0.4 (Voluven) may offer an alternative to pure fluid replacement solutions that are associated with problems after surgery including fluid overload an...
What is the current status of trial NCT02192502?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 149 participants. The study started on 2015-03. Estimated completion is 2020-02.
What interventions are being tested in trial NCT02192502?
The interventions under investigation include: human albumin 5% (DRUG), HES 130/0.4 (Voluven) (DRUG).
Who is sponsoring clinical trial NCT02192502?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.